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Abstract: Survivin is a critical regulator of mitosis, and an inhibitor of apoptosis which is 
  overexpressed in almost all cancers. In the current study, cell cycle profiles of normal   proliferating 
human umbilical vein endothelial cells, prostate cancer, and lung cancer cell lines   expressing 
varying levels of survivin and its splice variants were compared using a novel   functional 
complementation assay. Defects in chromosome segregation and cytokinesis that were observed 
after depletion of endogenous survivin were not complemented by any of the   survivin splice 
variants: survivin-2B, survivin-3B, survivin-∆Ex3, or survivin-2A when expressed   exogenously 
at a level comparable to endogenous full-length survivin. Survivin variants were not   detectable 
at the endogenous protein level. Cancer cells with higher levels of full-length survivin and 
survivin-2B expression, exhibited reduced caspase-3 activation following doxorubicin   treatment 
and radiation. Whereas earlier studies focused on function and expression levels of survivin 
specific to cancer cells, the current study brings forward the essential role of survivin in 
  normal dividing cells. Full-length survivin was found to be associated with Aurora-B kinase 
in the chromosomal passenger complex and depletion of survivin mimics mitotic phenotypes 
observed after Aurora-B kinase inhibition, in cancer as well as normal proliferating cells. 
Thus, our study establishes survivin as a marker of proliferation, rather than a cancer specific 
marker. Therefore, systemic therapeutic interventions targeting survivin will affect cancer as 
well as normal proliferating cells.
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Introduction
Survivin is highly expressed in human cancers but not detectable in non-  proliferating 
normal adult tissues.1 Considerable attention has been given to survivin as a 
target for cancer therapy because survivin expression levels in cancers are cor-
related with   pro-survival and proliferative functions, preventing apoptosis and 
promoting   mitosis. In cancer cell lines, survivin co-localizes with Aurora-B kinase, 
  Borealin, and inner centromere protein (INCENP) which are components of the 
chromosomal passenger complex (CPC).2,3 Aurora-B kinase is the enzymatic core 
of the CPC. In cancer cells, survivin expresses at a higher level during mitosis, and 
seems to function as a structural component of the CPC. Survivin should therefore 
facilitate the timely deployment of Aurora-B kinase at specific locations during 
mitotic progression for mitotic spindle assembly.4–6 However, the role of survivin in 
mitotic progression in normal cells is a matter of debate.
Considerable attention has been given to survivin as a target for sensitization of 
cancer cells to radiation and chemotherapeutic agents.7 Blocking the activation of 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
7
ORigiNAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OTT.S28147OncoTargets and Therapy 2012:5
caspases by direct binding is envisioned as a mechanism 
by which survivin confers resistance to apoptotic signals in 
cancers.8,9 The direct role of survivin in inhibition of apop-
tosis was originally proposed due to its homology to the 
family of inhibitors of apoptosis proteins (IAP) which have 
the capacity to bind to caspase-3 or caspase-7.1,3,9,10 Nonethe-
less, structurally, survivin is different from other mammalian 
IAPs, as it possesses only a single baculovirus IAP repeat 
domain and lacks the C-terminal RING finger and caspase 
  recruitment domains.1
In addition to the predominant 16 kDa full-length form 
of survivin, earlier studies have identified four low abundant 
transcripts generated by alternative splicing of survivin pre-
mRNA.11–14 A number of studies have been published on the 
possible roles of these splice variants in various cancers.15–21 
However, none have validated unequivocally these findings 
at the protein level with the use of specific antibodies in 
cancer cell lines or tissues. The variant, survivin-2B contains 
an additional 23 amino acid insertion from a cryptic exon, 
and at least two studies have proposed the possible role of 
this variant in promoting apoptosis.22–24 Survivin-∆Ex3 has 
been proposed as an anti-apoptotic protein.24,25 However, 
the relevance of each variant in the physiological context of 
mitosis or regulation of apoptosis has not been studied and 
is not understood. We have therefore developed a synthetic 
gene-based functional complementation assay to dissect 
the function of survivin and its variants at varying levels of 
expression, and investigated their function in the mitosis and 
regulation of apoptosis.
There are several ongoing efforts investigating the thera-
peutic potential of survivin, which include development of 
small molecule inhibitors and monoclonal antibody thera-
pies. However, several critical and fundamental questions on 
survivin biology remain unanswered, which include: (1) Is 
survivin essential for mitosis in both cancer as well as nor-
mal proliferating cells? (2) Do survivin splice variants play 
essential roles in cell division at physiological levels? and 
(3) What are the relative effects of survivin overexpression in 
mitosis versus inhibition of apoptosis? The development of 
a functional complementation assay and epitope tagging has 
allowed us to elucidate the physiological functions of survivin 
and variants as a regulator of cell division and apoptosis. In 
addition to its established roles in cancer cell proliferation, 
our studies clearly show that survivin is essential for prolif-
eration of normal cells. An increase in apoptosis following 
survivin depletion became evident only at time points fol-
lowing mitotic catastrophe suggesting that the primary role 
of survivin is mitosis rather than inhibition of apoptosis.
Materials and methods
Cell lines
Prostate cancer cell line PC3, and lung cancer cell line H466 
were purchased from ATCC (Manassas, VA) and grown at 
37°C with 5% CO2 in RPMI medium (Life Technologies, 
Carlsbad, CA) containing 10% fetal bovine serum (FBS) 
with 100u/mL penicillin and streptomycin. The HUVEC cells 
were purchased from   ScienCell (Carlsbad, CA), and cultured 
in ECM medium (ScienCell). Early passage cells (P2 to P6) 
were used in the experiments.
generation of cell lines
The survivin constructs were generated by PCR and other 
conventional molecular biology techniques. For making 
lentiviral vector particles, 293T cells were transfected with 
survivin genes in lentiviral expression vector pCDH (System 
Biosciences, Mountain View, CA) together with plasmids 
encoding VSV-G protein (Stratagene, Santa Clara, CA), 
a packaging construct derived from HIV p∆R8. Supernatants 
were collected, filtered, and used for infection using polybrene 
as cation and 48 hours later infected cells were selected with 
2 µg/mL puromycin for 72 hours.
Western blotting
50–70 µg protein from total extracts was used for probing with 
survivin (Cell Signaling, Danvers, MA [2808]; Novus, Littleton, 
CO [NB500-201]), Aurora-B kinase (Cell Signaling [3094]), 
Caspase-3 (R&D Systems, Minneapolis, MN [CPP32]), PARP 
(Cell Signaling [9542]), HA (Covance, Princeton, NJ [HA.11]) 
antibodies. Quantity One (v4.6.8; Bio-Rad, Hercules, CA) was 
used for quantitative relative signal intensity.
Apoptosis assays
Cells were treated with doxorubicin (0.5 µg or 1 µg/mL) 
irradiated with 6 to 8 gray x-rays from an RS-2000 Biological 
Irradiator (Rad Source, Suwanee, GA). Relative levels of 
apoptosis were compared using Annexin-V- FITC Apoptosis 
kit and APO-BrdU TUNEL assay kit (Life Technologies, 
Grand Island, NY).
Microscopy
Cells grown on coverslips were synchronized at G1/S 
phase by culturing in the presence of 2 mM thymidine for 
16 hours. Cells were released from thymidine block by 
washing twice and culturing in fresh medium for 6–8 hours, 
fixed with 4% paraformaldehyde, permeabilized with 
0.25% Triton X-100, and then stained with mouse monoclo-
nal anti-HA antibody (Covance: HA.11 at 1:400 dilution in 
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To compare the effects specific to each of the variants, a 
functional complementation assay was developed. A region 
in exon 2 that is common to all variants was identified as 
a target for small interfering RNA (siRNA) to knockdown 
endogenous survivin. Modified genes encoding full-length 
survivin or variants with seven silent mutations at the siRNA 
targeting site were introduced using a lentiviral expression 
system. Following selection, endogenous survivin was spe-
cifically knocked down by siRNA. Over 95% knockdown of 
5% BSA) and rabbit polyclonal anti-Aurora-B kinase (Cell 
Signaling: 3094 at 1:200 dilution in 5% BSA) antibody. 
Alexa Fluor 488   conjugated donkey   anti-mouse and Alexa 
Fluor 594 conjugated anti-rabbit (1:400, Life Technologies) 
antibodies were used for detecting the respective primary 
antibodies. Slides were mounted in 4’,6-Diamidino-2-
phenylindole (DAPI) containing medium and images were 
captured using a Zeiss CCD camera (AxioCam Mrm; New 
York, NY) attached to an ApoTome Microscope ([Axio 
Observer.Z1; Carl Zeiss MicroImaging GmbH, Jena, Ger-
many] 20× or 63× objective) using Zeiss Axiovision Vs40 
(v4.6.3.0) image acquisition software. Data were analyzed 
using Student’s t-test and were considered statistically 
significant if P , 0.05.
Small interference RNA and cell cycle 
analysis
Stealth siRNA oligonucletides targeting survivin was pur-
chased from Life Technologies. RNAiMax oligofectamine 
reagent from Life Technologies was used for siRNA trans-
fection according to the manufacturer’s protocol. Cells were 
collected at 48, 72, and 96 hours after siRNA, fixed with 70% 
methanol and prepared for flow cytometry in a BD (Franklin 
Lakes, NJ) FACSCalibur flow cytometer.
Results
Development of a functional 
complementation assay to evaluate 
survivin-variant specific effects on mitosis
Cell lines expressing varying levels of survivin (full-length), 
survivin-2B, survivin-3B, survivin-∆Ex3, and survivin-2A 
(Figure 1A) in prostate (PC3) and lung (H466) cancer cell 
lines, as well as normal human umbilical vein endothelial 
cells (HUVEC) were generated. Relative levels of   expression 
of each variant and full-length survivin were compared by 
Western blot analysis using an antibody detecting a conserved 
N-terminal region. Over 38-fold overexpression of survivin 
and survivin-2B could be achieved by repeated infection with 
lentiviral particles. However, overexpression of survivin-3B, 
survivin-∆Ex3, and survivin-2A could not be achieved even 
after repeated infection (Figure 1B, Supplemental Figure 1C), 
potentially due to a dominant negative effect associated with 
these variants, which contain most of the dimerization domain. 
Similar levels of survivin and variant proteins were obtained 
following infections with viral particles for expression of 
untagged as well as an N-terminal FLAG-HA epitope tagged 
survivin (Figure 1B and Supplemental Figure 1B and C).
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Figure  1  Development  of  the  functional  complementation  assay  and  validation 
of  expression  of  the  survivin  variants.  (A)  Diagrammatic  representation  of  the 
organization of human survivin gene. Splice variant survivin-2B has an extra exon 
with  23  amino  acids  inserted  after  exon  2.  Survivin-3B  has  seven  amino  acids 
introduced after exon 3 and exon 4 are deleted. Survivin-∆Ex3 has an altogether 
different sequence at the C-terminus due to a frame shift mutation. Survivin-2A has 
only the first two exons. (B) Western blots detecting expression of the full-length 
survivin and variants in PC3 cells, using an antibody against N-terminal region capable 
of detecting all variants and full-length survivin. The upper panels show the survivin 
levels 72 hours after transfection with siRNA oligonucleotide specifically targeting 
endogenous survivin, and the lower panel shows the relative levels of endogenous 
and the introduced survivin before transfection. Overexpression of FLAg-HA tagged 
full-length survivin WT (lane 3), surivin-2B (lane 4) and relatively lower levels of 
survivin-3B (lane 5), survivin-∆Ex3 (lane 6), and survivin-2A (lane 7). Smaller derivative 
products of survivin (less than 10%, were detected in cells with very high levels of 
expression) as reported from earlier studies that used overexpression approaches.
Note: The survivin signal in control cells shows over 95% reduction of endogenous 
survivin.
Abbreviations: NT, non-targeting control; –eSur, endogenous survivin.
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the endogenous survivin protein was observed 72 hours after 
siRNA, with no apparent reduction in the signal from the 
introduced gene (Figure 1B and Supplemental Figure 1C). 
This allowed the evaluation of mitotic effects that are specific 
to the expression of individual variants. In addition, this has 
also allowed the comparative analysis of apoptotic regula-
tory effects of survivin overexpression following exposure 
to radiation or chemotherapeutic agent doxorubicin.
B
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Figure 2 Effects of individual survivin variants on mitosis and cytokinesis after siRNA targeting the endogenous survivin. Representative FACS profile of PC3 (A) and human 
umbilical vein endothelial cells (B) showing survivin dependent effects as changes in cell cycle stages and polyploidy. Cell cycle stages, DNA content (2N, 4N, and #8N), 
percent polyploidy observed 72 hours after the siRNA targeting endogenous survivin, analyzed from 10,000 cells are marked. (C) Representative images showing nuclear 
morphology with increase in multilobed nuclei in PC3 cells as marked at 72 hours after siRNA detected by DAPi staining.
Abbreviations: FACS, fluorescence activated cell sorting; NT, non-targeting siRNA control; –eSur, endogenous survivin.
Full-length survivin is essential  
and sufficient for cell division
The cell cycle profile in cells with varying levels of expres-
sion was compared by flow cytometry (Figure 2A and B) 
in normal cells as well as cancer cells. Even in cells with 
over 100-fold overexpression of full-length survivin, no 
significant difference in cell cycle profiles could be detected 
relative to control cells. Mitotic defects and alterations in cell 
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cycle profiles due to the depletion of endogenous survivin 
were evident from the gradual increase in the percentage of 
cells with 4N (G2/mitosis) and 8N (multinucleated) DNA 
content at various time points after siRNA. In PC3 cells, 
comparison to the background level which had an average 
of 9% polyploidy in cells transfected with a non-targeting 
scrambled oligonucleotide control, an average of 25.3%, 
43.6%, and 51.5% polyploidy was detected respectively at 
48, 72, and 96 hours after siRNA transfection (Figure 2A 
and Supplemental Figure 2). Similar cell cycle profile and 
levels of polyploidy were observed in cells expressing the 
variants survivin-3B, survivin-∆Ex3, and survivin-2A, 
(  Figure 2A and Supplemental Figure 2), suggesting that these 
variants are defective for mitotic function. All experiments 
were repeated independently at least three times. Consistent 
with the increase in polyploidy detected by flow cytometry, 
the nuclear volume and multilobed nuclear structure were 
evident from DAPI staining (Figure 2C). The chromosome 
segregation defects and mitotic catastrophe resulting from 
expression of each of variants alone were further quantified 
by counting the multilobed nuclei from DAPI stained cells 
after siRNA transfection (72 hours after siRNA: P-values: 
3B: 0.00012; ∆Ex3: 0.00001, 2A: 0. 012, WT: 0.28; 2B: 
0.0735). Similar cell cycle profiles were obtained from early 
Survivin Aur-B DNA Overlay
Prophase
Pro-
metaphase
Metaphase
Anaphase
Telophase
G1/
Cytokinesis
Figure 3 Functional CPC association of survivin with Aurora-B kinase during mitosis in human umbilical vein endothelial cells. Cells expressing N-terminal FLAg-HA tagged 
full-length survivin, at various stages in mitosis were co-stained with anti-HA (green) and Aurora-B kinase (red) antibodies, and DNA counterstained with DAPi.
Abbreviation: CPC, chromosomal passenger complex.
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passage HUVEC cells expressing variants alone (Figure 2B), 
confirming that full-length survivin with intact C-terminal 
domain is essential for mitotic progression in normal cells as 
well. Thus, the internally controlled functional complemen-
tation assay conducted in cancer as well as normal proliferat-
ing cells confirmed that full-length survivin is essential for 
chromosome   segregation and cytokinesis.
Survivin-2B, the only variant which contains C-terminal 
microtubule binding domain, was able to partially execute 
the mitotic function, when expressed at a very high and 
physiologically unachievable level (Supplemental Figure 2B). 
However, at a level equivalent to that of endogenous full-
length survivin, survivin-2B was not sufficient for rescuing 
completely the mitotic defects resulting from depletion of 
endogenous survivin (Figure 2A). Thus, analysis of cells with 
varying levels of expression of survivin-2B confirmed that 
full-length wild type survivin is essential for mitotic function 
in the physiological context.
Expression of C-terminal truncation variants survivin-3B, 
survivin-∆Ex3, and survivin-2A individually at a level near 
to the endogenous full-length survivin   (Figure 2A and B) 
exhibited abnormal mitotic phenotypes in both PC3 as well 
as HUVEC cells. The cell division defects were similar to 
that observed in control knockdowns, with more than 40% 
of cells having 8 N or higher DNA content 72 hours post 
siRNA transfection (Figure 2). Mitotic catastrophe and chro-
mosome segregation defects were evident from the marked 
increase in multinucleated cells as compared by fluorescence 
activated cell sorting (FACS) analysis and DAPI staining 
and microscopy. An increase in the population of sub-G1 
apoptotic cells was observed in these cells 96 hours after 
siRNA (Supplemental Figure 2). The increases in sub-G1 
fraction were detected only at later time points (96 hours 
post siRNA), suggesting that the induction of apoptosis is 
primarily due to mitotic catastrophe, rather than the direct 
inhibition of caspases by survivin.
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Figure 4 Subcellular localization of survivin variants. (A) Western blot showing the expression of FLAg-HA tagged survivin in human umbilical vein endothelial cells detected 
using survivin and HA antibodies. (B) Localization of survivin variants in human umbilical vein endothelial cells at stages in mitosis co-stained with Aurora-B kinase and 
counterstained with DAPI. Immunofluorescence of full-length survivin and survivin-2B stained with Aurora-B kinase and DAPI in H466 (C) and PC3 (D) cell lines.
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Association of survivin with the CPC  
is essential for mitosis in normal  
as well as cancer cells
To determine whether or not the association of survivin with 
the CPC is essential for cell division in non-cancerous, but 
proliferating cells, we used immunofluorescence (IF) and 
genetic approaches. Proliferating early passage HUVEC cells 
expressing epitope-tagged survivin were used to examine 
its localization during various stages of mitosis. Given our 
findings that N-terminal tags do not affect mitotic function, 
N-terminally FLAG-HA tagged proteins were used for 
localization studies.
IF studies clearly showed that full-length survivin is 
associated with Aurora-B kinase, with a characteristic pat-
tern of CPC movement during mitotic progression (Figure 3). 
Survivin was found co-localized with Aurora-B kinase in the 
centromere during prometaphase and metaphase; spindle 
midzone during anaphase and at the midzone in telophase 
and cytokinesis. Survivin and Aurora-B kinase were co-
localized at all stages in mitosis and cytokinesis in over 95% 
of the cells examined (Supplemental Figure 3A). Even under 
conditions of overexpression of survivin, signals were specifi-
cally localized with Aurora-B kinase. The CPC association 
of survivin during mitotic spindle assembly and progression 
in cancer as well as normal cells were confirmed by real time 
video microscopy using green fluorescence protein (GFP) 
tagged full-length survivin in PC3 as well as HUVEC cells 
(data not shown). This data confirmed that survivin and Auro-
ra-B kinase are associated with the same machinery, essential 
for proliferation in cancer cells as well as normal cells.
WT – Over expressed
+WT C
Actin
Survivin
+2B
+WT
6 Gray
80 hrs Untreated
Doxorubicin
0.5 µM−72 hrs
cPARP
Load
control
cCasp3
PARP
C +2B +WT +WT CC +2B +2B
C
B A
100
90
80
70
60
50
40
30
20
10
0
2B – Over expressed
Control – Empty vector
TUNEL positive TUNEL negative
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
e
l
l
s
Figure 5 Effect of full-length survivin and survivin-2B overexpression on apoptosis in PC3 cells. (A) Western blots showing the overexpression of survivin and survivin-2B. 
(B) Reduction in cleaved caspase-3 (cCasp3) and cleaved PARP (cPARP) with overexpression of survivin in irradiated and doxorubicin treated cells and control. Signals were 
normalized using an internal load control and the relative levels of uncleaved to cleaved PARP were quantified. A 2.3-fold reduction in cleaved PARP was detected in cells with 
survivin overexpression, treated with a suboptimal dose of doxorubicin (0.5 µM, 72 hours). Variations found with radiation (8 Gy, 80 hours) were not significant. A 0.7-fold 
reduction in cleaved Caspase-3 signal was detected in cells over expressing full-length survivin treated with doxorubicin (0.5 µM for 72 hours). (C) Relative levels of DNA 
fragmentation detected by TUNEL assay 72 hours after 1 µM doxorubicin treatment.
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Survivin variants are detected primarily  
in the cytoplasm during mitosis
The subcellular localization of survivin and its splice variants 
has been extremely difficult because the available antibodies 
cross-reacted with a number of nuclear as well as cytoplas-
mic proteins (Supplemental Figure 1A, and data not shown). 
Therefore, cells expressing epitope tagged survivin variants 
were generated to circumvent possible errors in detection 
and quantification. Protein expression levels of the respective 
variants were confirmed by Western blotting using HA as well 
as survivin antibody (Figure 4A).   Subcellular localization of 
each of the variants during mitosis was determined by indirect 
IF using HA and Aurora-B kinase antibodies. IF has shown 
that, during the mitotic phase, full-length survivin localizes 
in the nucleus; survivin-2B in the nucleus as well as in cyto-
plasm; while survivin-3B, survivin-∆Ex3, and survivin-2A 
are primarily in the   cytoplasm (Figure 4B and Supplemental 
Figure 3B–D). A small fraction of survivin-2B was found 
associated with CPC, which was apparent from partial co-
localization with Aurora-B kinase at the midbody during 
cytokinesis. This was consistent with the findings from flow 
cytometry analysis of survivin-2B expressing cells (Figure 2). 
A similar localization pattern for variants were observed in 
PC3 and H466 cancer cells   (Figure 4C and D). Thus, flow 
cytometry data and microscopy following epitope tagging 
shows that at the physiological level only full-length survivin 
is associated with Aurora-B kinase in CPC. Functional asso-
ciation of survivin variants with any specific cellular compart-
ment such as mitochondria could not be established.
Full-length survivin and survivin-2B 
overexpression inhibits apoptosis  
in cancer cells
Since the inhibition of apoptosis is proposed to contrib-
ute to therapeutic resistance in cancer cells, the effect of 
overexpression of full-length survivin and survivin-2B on 
apoptosis was compared in cancer cells. PC3 cells stably 
expressing higher levels of survivin and survivin-2B (104- 
and 38-fold respectively, Figure 5A), and an empty vector 
control were used to investigate their effects on the inhibi-
tion of apoptosis. In this experiment, cell lines express-
ing C-terminal truncation variants could not be included 
because of the dominant negative effect of these variants. 
To compare the expression level dependent apoptosis inhibi-
tion, cells over expressing survivin and survivin-2B were 
treated in parallel with a single dose of radiation, collected 
at various time points, and relative levels of cleaved PARP 
and cleaved caspase-3 signals were compared. A nominal 
decrease in radiation induced apoptosis was observed in 
cells over expressing full-length survivin and to a lesser 
extent even in survivin-2B cells as seen by the decrease 
in cleaved PARP signal (Figure 5B). The effect of over-
expression of survivin and survivin-2B in doxorubicin 
induced apoptosis was also compared using the Annexin-V/
propidium iodide-based apoptosis assay. However, the apop-
totic inhibitory effect detected in survivin or survivin-2B 
overexpression cells was not substantial (Supplemental 
Figure 4, and data not shown).
Since the inhibitory effect of survivin on radiation 
induced apoptosis detected from two different assays 
was not substantial, we compared the effects of the topoi-
somerase II inhibitor, doxorubicin. Doxorubicin treatment 
provides a consistent level of damage over the course of the 
experiment and hence is expected to cause higher levels 
of apoptosis. Reduction in cleaved caspase-3 (0.7-fold) 
and cleaved PARP signals (2.3-fold) in full-length sur-
vivin over expressing cells treated with a suboptimal 
dose of doxorubicin (0.5 µM, 72 hours) were observed 
(Figure 5B). Consistent with this, a significant reduction 
(2.4-fold) in DNA fragmentation was detected from a 
TUNEL-based assay (APO BrdU kit, Life Technologies) 
in cells with full-length survivin overexpression, when 
assayed 72 hours after treatment with 1 µM doxorubicin 
(Figure 5C). The apoptosis inhibitory effect of survivin 
and survivin-2B were similar. Of note, contrary to the pre-
vious reports,16,23 no pro-apoptotic effects of survivin-2B 
were detected in our internally controlled experiments 
(Figure 5B).
The apoptotic inhibitory effect of survivin overexpres-
sion following radiation damage was also investigated by 
comparing protein markers (cleaved caspase-3 and cleaved 
PARP), Annexin V , and TUNEL assays in cells collected at 
various time points (36 hours to 96 hours) following varying 
doses of radiation (6 gray to 10 gray). However, the inhibi-
tion of radiation induced apoptosis detected in survivin or 
survivin-2B overexpression observed were not significant 
(data not shown). The differences in the levels of apoptotic 
inhibition from radiation versus doxorubicin treated cells 
were predicted due to the intensity of the damage, timing, 
and mechanism of induction of apoptosis. While many of the 
DNA breaks incurred by single dose radiation damage get 
promptly repaired, continuous DNA damage is expected from 
doxorubicin. Moreover, cell death by radiation is primarily 
mediated through mitotic catastrophe rather than due to DNA 
breaks, as most breaks are usually repaired within hours. 
Apoptosis following radiation treatment in these cells are 
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likely the result of mitotic catastrophe as cells attempt to 
undergo mitosis with misrepaired lesions. Thus, variations 
in the levels, timing, and detection of these signals were 
expected. Taken together, these data confirm that, while 
full-length survivin is essential for mitotic progression, 
the projected apoptotic regulatory effects of survivin or 
survivin-2B are nominal.
Discussion
The genetic studies presented in this paper shed light on 
several outstanding questions on the biology of survivin. 
Our studies clearly show that survivin splice variants, even 
when present at higher levels, do not contribute significantly 
to pro-survival or proliferative functions in cancer cells such 
as promoting mitosis and inhibition of apoptosis. Thus, the 
significance and relevance of survivin variants as a prognos-
tic or predictive marker are questioned.13,19,21,26–37 Splicing 
is a posttranscriptional event and a proportional increase in 
variants is expected when the survivin promoter is activated. 
Altered levels of splice variants are expected if mutations 
and polymorphism in the regulatory elements that regulate 
splicing are present.
The current genetic studies establish that the C-terminal 
microtubule binding region of survivin is essential for 
chromosome segregation and completion of cell division. 
Survivin functions as a dimer with a tie-knot like structure 
in the CPC, and C-terminal coiled-coiled structure of both 
molecules are likely essential for microtubule binding. The 
relative abundance of variants that can dimerize with full-
length survivin and lack the C-terminal domain are predicted 
to modulate CPC function.
The exact mechanism by which higher levels of sur-
vivin promote proliferation and survival of cancer cells, 
conferring resistance to therapy is still not fully clear. 
Studies in model systems have shown that survivin-like 
IAP molecules predominantly participate in cytokinesis, 
associated with Aurora-B kinase and mitotic machinery.38,39 
Even when overexpressed, survivin signals were found 
localized to Aurora-B kinase and hence survivin is likely 
a limiting factor for promoting cell growth. Higher levels 
of survivin likely provide an enhanced structural integrity 
to mitotic machinery, potentially helping to bypass the 
mitotic spindle checkpoints common in cancers. Enhanced 
structural support provided by higher levels of survivin 
could be contributing to better centromere and kinetochore 
attachment, bipolar spindle formation, and cytokinesis. 
Survivin overexpression likely provides better integrity 
and structural support to the CPC and this helps to deliver 
Aurora-B kinase at its destined locations during mitotic 
events. Aurora-B kinase is required for phosphorylation 
of mitotic regulators, which include histone H3 at serine 
10 and centromere protein CENP-A which are critical for 
chromatin condensation. The other targets include micro-
tubule destabilizing Kin I kinesin and MCAK, important 
for spindle assembly.
The present study further established that survivin is 
essential for cell division in cancers as well as normal 
cells. Identifying survivin as a marker for proliferation is 
consistent with reports showing elevated levels of survivin 
during liver regeneration following hepatectomy.40 In nor-
mal cells, the expression of survivin from the endogenous 
promoter is restricted to the G2/M phase of the cell cycle. 
Given that most adult normal tissues are not proliferating, 
it has been difficult to detect survivin in normal adult tis-
sues. The systemic approaches targeting survivin in cancers 
may affect proliferating normal cells as well and future 
studies should focus on a more targeted approach specific 
to cancer cells.
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Figure S1 (A) Western blot showing non-specific immunoreactivity of two commonly used commercial survivin antibodies, in extracts made from several cell lines as marked. 
Lanes 1, 2, 3: Total extract from human umbilical vein endothelial cells, H466, and PC3 cells probed with anti-survivin rabbit monoclonal antibody (Cell Signaling: 2808), 
Lane 4: PC3 extracts probed with anti-survivin polyclonal antibody from Novus Biological (NB-500-201). Endogenous survivin (lower band) and non-specific signals are marked; 
(B) Western blot detecting full-length survivin, survivin-2B and survivin-3B at a level comparable to the endogenous survivin and actin was used as loading control; (C) Western 
blot detecting expression of untagged survivin and all the variants in PC3 cells. The upper panel: survivin levels 72 hours after transfection with siRNA oligonucleotide specifically 
targeting the endogenous survivin (knock down efficiency .95%) and the lower panel shows the levels of endogenous and introduced survivin before transfection.
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functional endogenous survivin as marked.
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Figure S3 (A) A broader view of immunostaining showing co-localization of survivin with Aurora-B kinase in human umbilical vein endothelial cells during mitosis. green: 
Survivin, Red: Aurora-B kinase, Blue: DAPi. (B–D) Immunofluorescence demonstrating predominant cytoplasmic localization of survivin variants. Human umbilical vein 
endothelial cells expressing respective FLAg-HA-tagged proteins were stained with HA, Aurora-B antibodies, and DAPi.
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collected 96 hours after exposed to 6 gray.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
20
Jacob et al